Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy

Intervirology

Volumn 57, Issue 3-4, 2014, Pages 202-211

  Gerlich, Wolfram H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antiviral therapy; Entecavir; Healthcare providers; Hepatitis B; Hepatitis B virus chronic carrier; Hepatitis B virus infectivity; Hepatitis Bvirus DNA; Mother to child transmission; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ADENINE; GUANINE; HEPATITIS B(E) ANTIGEN; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DISEASE DURATION; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; SCREENING; TERATOGENICITY; VERTICAL TRANSMISSION; VIRUS CARRIER; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; BLOOD; DISEASE TRANSMISSION; DRUG EFFECTS; FEMALE; HEPATITIS B, CHRONIC; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; TRANSMISSION; VIREMIA; VIROLOGY; VIRUS LOAD; INFECTION RISK; REDUCTION; VIRUS INFECTIVITY;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEALTH PERSONNEL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE; VIRAL LOAD; VIREMIA;

HEPATITIS B VIRUS;

EID: 84904690481     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360949     Document Type: Article

References (61)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST: Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
2. Gerlich WH: Medical virology of hepatitis B: how it began and where we are now. Virol J 2013; 10: 239.
3. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY: Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006; 46: 1829- 1835.
4. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C: Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988; 62: 4136-4143.
5. Petersen J, Dandri M, Gupta S, Rogler CE: Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci USA 1998; 95: 310-315.
6. Alter HJ, Seeff LB, Kaplan PM, McAuliffe VJ, Wright EC, Gerin JL, Purcell RH, Holland PV, Zimmerman HJ: Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976; 295: 909- 913.
7. Beasley RP, Hwang LY, Szmuness W, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS: HBIG prophylaxis for perinatal HBV infections - final report of the Taiwan trial. Dev Biol Stand 1983; 54: 363-375.
8. Milich DR, Chen MK, Hughes JL, Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998,160: 2013-2021.
9. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591.
10. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A; WHO Collaborative Study Group: An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001; 80: 63-71.
11. Baylis SA, Heath AB, Chudy M, Pisani G, Klotz A, Kerby S, Gerlich W: An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology-based assays. Vox Sang 2008; 94: 358-362.
12. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R: Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. J Clin Microbiol 1999; 37: 68-73.
13. Chudy M, Hanschmann KM, Kress J, Nick S, Campos R, Wend U, Gerlich W, Nubling CM: First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol 2012; 55: 303-309.
14. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, Chisari FV: The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652-9662.
15. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H: Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008,80: 2064-2068.
16. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, Imai M, Mayumi M, Moritsugu Y: Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136: 571- 576.
17. Corden S, Ballard AL, Ijaz S, Barbara JA, Gilbert N, Gilson RJ, Boxall EH, Tedder RS: HBV DNA levels and transmission of hepatitis B by health care workers. J Clin Virol 2003; 27: 52- 58.
18. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshoj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M: Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013; 53: 1405- 1415.
19. Gerlich WH: Hepatitis B und C - Ubertragungsrisiko auf Patienten durch infiziertes medizinisches Personal. Bundesgesundheitsblatt 2004: 47: 369-378.
20. Enfield KB, Sharapov U, Hall KK, Leiner J, Berg CL, Xia GL, Thompson ND, Ganova- Raeva L, Sifri CD: Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. Clin Infect Dis 2013; 56: 218- 224.
21. Deutsche Vereinigung zur Bekampfung der Viruskrankheiten e.V. DVV. Empfehlungen der Deutschen Vereinigung zur Bekampfung der Viruskrankheiten (DVV) zur Pravention der nosokomialen Ubertragung von Hepatitis B Virus (HBV) und Hepatitis C Virus (HCV) durch im Gesundheitswesen Tatige. http:// www.dvv-ev.de/TherapieempfMerkbl/hbvhcv. pdf.
22. Department of Health. Hepatitis B infected healthcare workers and antiviral therapy. 2007. http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/ DH-073164.
23. American College of Surgeons. Statement on the surgeon and hepatitis. Bulletin of the American College of Surgeons, April 2004, vol 89, No. 4. http://www.facs.org/fellows-info/statements/st-22.html.
24. Henderson DK, Dembry L, Fishman NO, et al: SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus. Infect Control Hosp Epidemiol 2010; 31: 203-232.
25. CDC: Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR. Recommendations and Reports, July 6, 2012, vol 61, No. 3. Continuing Education Examination. http://www.cdc.gov/mmwr/cme/ conted.html.
26. Gunson RN, Shouval D, Roggendorf M, et al: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003; 27: 213-230.
27. Buster EH, van der Eijk AA, Schalm SW: Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions. Antiviral Res 2003; 60: 79-85.
28. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
29. Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver: Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012; 26: 917- 938.
30. Buster EH, van der Eijk AA, de Man RA, Janssen HL, Schalm SW: Prolonged antiviral therapy for hepatitis B virus-infected health care workers: a feasible option to prevent work restriction without jeopardizing patient safety. J Viral Hepat 2007; 14: 350-354.
31. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD: No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59: 434-442.
32. Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF: Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after five years of entecavir treatment. J Gastroenterol Hepatol 2013, DOI: 10.1111/jgh.12476.
33. Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC: Assessment of current criteria for primary non-response in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2013, DOI: 10.1002/hep.26910.
34. Kwon DH, Kim IH, Choung BS, Ahn DS, Yoo SH, Park SB, Lee S, Kim SH, Kim SW, Im YJ: Continuous long-term entecavir therapy in naive chronic hepatitis B patients showing partial virologic response. Gut Liver 2013; 7: 712-718.
35. Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR: Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat 2012; 19: 213-219.
36. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E: Randomized comparison of tenofovir disoproxil fumarate versus emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980-988.e1.
37. Buster EH, Baak BC, Bakker CM, Beuers UH, Brouwer JT, Drenth JP, van Erpecum KJ, van Hoek B, Honkoop P, Kerbert-Dreteler MJ, Koek GH, van Nieuwkerk KM, van Soest H, van der Spek BW, Tan AC, Vrolijk JM, Janssen HL: The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. Neth J Med 2012; 70: 381-385.
38. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF Jr, McHutchison JG, Manns M: Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014; 60: 715-722.
39. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
40. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P: Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013; 58: 505-513.
41. Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, Akkoyunlu Y: Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci 2013; 17: 2467-2473.
42. Bzowej NH: Optimal management of the hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep 2012; 11: 82-89.
43. Pan CQ, Lee HM: Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis 2013; 33: 138-146.
44. Piratvisuth T: Optimal management of HBV infection during pregnancy. Liver Int 2013; 33(Suppl 1):188-194.
45. Ding Y, Sheng Q, Ma L, Dou X: Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J 2013; 10: 17.
46. Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D: Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014; 60: 523-529.
47. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, Tong MJ: An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10: 452-459.
48. Xu H, Zeng T, Liu JY, Lei Y, Zhong S, Sheng YJ, Zhou Z, Ren H: Measures to reduce mother- to-child transmission of hepatitis B virus in China: a meta-analysis. Dig Dis Sci 2014; 59: 242-258.
49. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL: Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297.
50. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW: A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011; 17: 4321-4333.
51. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M: Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
52. Ayres A, Yuen L, Jackson KM, Manoharan S, Glass A, Maley M, Yoo W, Hong SP, Kim SO, Luciani F, Bowden DS, Bayliss J, Levy MT, Locarnini SA: Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat 2013, DOI: 10.1111/jvh.12212.
53. Yi W, Liu M, Cai HD: Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World J Gastroenterol 2012; 18: 6645-6650.
54. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, Ruan B: The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 2012; 9: 185.
55. Liu M, Cai H, Yi W: Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 2013; 20(suppl 1): 65-70.
56. Wang L, Kourtis AP, Ellington S, Legardy- Williams J, Bulterys M: Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis 2013; 57: 1773-1781.
57. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, Ghany MG, Reddy KR: Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57: 2423-2429.
58. Richtlinien des Bundesausschusses der Arzte und Krankenkassen uber die arztliche Betreuung wahrend der Schwangerschaft und nach der Entbindung ('Mutterschafts-Richtlinien'). Bundesanzeiger AT 22.08. 2013 B2, 23. August 2013.
59. Grosheide PM, Wladimiroff JW, Heijtink RA, Mazel JA, Christiaens GC, Nuijten AS, Schalm SW: Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis. BMJ 1995; 311: 1197-1199.
60. Godbole G, Irish D, Basarab M, Mahungu T, Fox-Lewis A, Thorne C, Jacobs M, Dusheiko G, Rosenberg WM, Suri D, Millar AD, Nastouli E: Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals. BMC Pregnancy Childbirth 2013; 13: 222.
61. Giles ML, Grace R, Tai A, Michalak K, Walker SP: Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: current standards of care. Aust NZ J Obstet Gynaecol 2013; 53: 231-235.